Executive Viability Abstract
This feasibility study evaluates the development of a centralized, AI-powered diagnostic platform in Singapore, designed to assist clinicians in early-stage disease detection through radiological and genomic data analysis. Leveraging Singapore's robust digital health infrastructure and government support (e.g., AI Singapore and HSA regulatory frameworks), the project shows high potential for integration within the local healthcare ecosystem. The financial outlook is positive, driven by a B2B SaaS model targeting private healthcare providers and public healthcare clusters (SingHealth, NHG, NUHS).
Return on Investment
145% (5-Year Projection)
Payback Span
2.8 years
Net Present Value
SGD 4,200,000
IRR Index
26.4%
## Market Analysis
Singapore's HealthTech market is projected to grow at a CAGR of 12.5% through 2030. The aging population and the government's 'Healthier SG' initiative create a strong demand for predictive diagnostics. Competitor analysis shows a gap in localized AI models trained on Asian phenotypes, providing a significant competitive advantage.
## Technical Feasibility
The platform will utilize deep learning architectures deployed on high-performance cloud clusters (AWS Singapore Region) to ensure low latency and PDPA compliance. Integration will follow HL7 FHIR standards for interoperability with National Electronic Health Records (NEHR). Initial prototypes indicate a diagnostic accuracy of 94% for pulmonary screenings.
## Financial Projections
Estimated total investment (CAPEX) is SGD 3.5 million over 24 months. Revenue is projected to scale from SGD 1.2M in Year 2 to SGD 8.5M by Year 5. The primary revenue streams include per-scan licensing fees and annual maintenance contracts.
## Risk Assessment
Key risks include prolonged HSA (Health Sciences Authority) Class B/C medical device registration timelines and potential data breaches. Mitigation strategies include early engagement with the Pre-Market Consultation Scheme and implementation of Zero-Trust architecture.